NEW YORK (GenomeWeb News) – Abbott has obtained the rights to distribute freeze-dried HLA-typing kits from Biofortuna as part of an agreement announced today.
Under the terms of the deal, Biofortuna will design, develop, and manufacture a range of the kits called SSPGo. Upon regulatory approvals, Abbott will have exclusive distribution rights in the US and all other geographies, excluding France, Spain, Portugal, and the Benelux countries. Along with SSPGo products, interpretation software called Verdict, kit updates, and improvements are covered by the deal.
Financial terms were not disclosed.
Biofortuna, a molecular diagnostics firm based in Liverpool, UK, which said in February it had raised about $1.6 million, has freeze-drying capabilities that result in diagnostic kits that are stable at ambient temperature for up to 16 months. This eliminates the need for refrigerators, freezers, and temperature-controlled shipping.
The SSPGo products are the firm's first freeze-dried HLA typing kits of its kind, Biofortuna said, and will be available to laboratories outside the US and for order from Abbott starting in June. The kits are CE-marked and have been submitted for approval by the US Food and Drug Administration.